AxoGen Reports Strong 2024 Financial Growth and FDA Progress

An update from AxoGen ( (AXGN) ) is now available.

Axogen, Inc. reported its financial results for the fourth quarter and full year of 2024, showing significant growth with a 15.1% increase in fourth-quarter revenue compared to the previous year and a 17.8% increase in full-year revenue. The company achieved a net income of $0.4 million for the quarter and an adjusted net income of $5.9 million for the full year. Axogen’s CEO, Michael Dale, expressed satisfaction with the results and highlighted the company’s strategic focus on expanding its work in peripheral nerve function restoration. The FDA accepted Axogen’s Biologics License Application for Avance® Nerve Graft, with anticipated approval in September 2025, which could further enhance the company’s market position.

More about AxoGen

Axogen, Inc. is a leading company focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company’s product portfolio includes innovative solutions such as the Avance® Nerve Graft and Axoguard Nerve Connector®, which are used in both scheduled and emergent trauma procedures to restore peripheral nerve function and improve patients’ quality of life. Axogen’s products are available in several countries, including the United States, Canada, and Germany.

YTD Price Performance: 9.82%

Average Trading Volume: 413,006

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $792.6M

For detailed information about AXGN stock, go to TipRanks’ Stock Analysis page.